Richard D. Baird
Cambridge, ENG CB20RE, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.
Journal: ESMO open
Published: October 27, 2025
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2025
Using circulating tumor DNA as a novel biomarker of efficacy for dose-finding designs in oncology.
Journal: Statistical methods in medical research
Published: July 01, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Journal: Nature communications
Published: March 06, 2025
Modern Clinical Trials: Seamless Designs and Master Protocols.
Journal: Cancer medicine
Published: March 04, 2025
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.
Journal: Nature cancer
Published: February 11, 2025
Last Updated: 09/26/2026